CYP2C19

POPular Genetics

This randomized, prospective trial of 2,488 patients undergoing primary PCI with stent implantation assessed the use of a genotype-guided approach to oral P2Y12 inhibitor selection.
This study showed that a genotype-guided approach to therapy was noninferior to standard treatment with ticagrelor or prasugrel with respect to thrombotic events, and resulted in a lower incidence of bleeding.
Considering that ticagrelor/prasugrel cost 10-20X more than generic clopidogrel, CYP2C19 genotyping can significantly lower healthcare costs.
The POPular Genetics trial used Spartan’s RX CYP2C19 System.

Explore Related Resources